Anna Näger is currently a Clinical Research Associate II at ICON plc since August 2025, with prior experience that includes a range of research positions and clinical roles. Anna's research background features internships at Academia Sinica and the Technical University of Munich, focusing on peptide therapy for prion diseases and adoptive T-cell therapy for chronic HBV infection, respectively. A PhD in Molecular Life Sciences was earned at EPFL, emphasizing human telomeres and associated genomic stability research. Previous clinical experiences include positions at IQVIA as a Clinical Research Trainee and Clinical Research Associate I, where responsibilities included site management, trial monitoring, and ensuring compliance with regulatory requirements. Academic qualifications encompass a Master of Science in Molecular Biotechnology and a Bachelor of Science in Molecular Biotechnology from the Technical University of Munich, complemented by a brief academic engagement at the National University of Singapore.
Location
Biel, Switzerland
This person is not in the org chart
This person is not in any offices